Mutational spectrum in a worldwide study of 29,700 families with<i>BRCA1</i>or<i>BRCA2</i>mutationsTimothy R. Rebbeck, Carole Brewer, Ángela R. Solano et al.|Human Mutation|2018Cited by 319
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancerAntoinette Hollestelle, Saundra S. Buys, Frederieke H. van der Baan et al.|Gynecologic Oncology|2015Cited by 20
The impact of estrogen depletion by aromatase inhibitors on adiponectin serum levels in postmenopausal patients with breast cancer.Georg Pfeiler, Peter Dubsky, Robert Königsberg et al.|Journal of Clinical Oncology|2013Cited by 4
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.Elena Vigorito, Anne‐Marie Gerdes, Karoline Kuchenbaecker et al.|Apollo (University of Cambridge)|2016Cited by 0